| Literature DB >> 27510283 |
Gaëlle Wambiekele Kiyeko1, Eric Hatterer1, Suzanne Herren1, Irene Di Ceglie2, Peter L van Lent2, Walter Reith3, Marie Kosco-Vilbois1, Walter Ferlin1, Limin Shang4.
Abstract
Increased expression of endogenous Toll-like receptor 4 (TLR4) ligands (e.g., Tenascin-C, S100A8/A9, citrullinated fibrinogen (cFb) immune complexes) has been observed in patients with rheumatoid arthritis (RA). However, their roles in RA pathogenesis are not well understood. Here, we investigated the expression kinetics and role of endogenous TLR4 ligands in the murine model of collagen-induced arthritis (CIA). Tenascin-C was upregulated in blood early in CIA, and correlated positively with the clinical score at day 56. Levels of S100A8/A9 increased starting from day 28, peaking at day 42, and correlated positively with joint inflammation. Levels of anti-cFb antibodies increased during the late phase of CIA and correlated positively with both joint inflammation and cartilage damage. Blockade of TLR4 activation at the time of the first TLR4 ligand upregulation prevented clinical and histological signs of arthritis. A TLR4-dependent role was also observed for Tenascin-C and cFb immune complexes in osteoclast differentiation in vitro. Taken together, our data suggests that the pathogenic contribution of TLR4 in promoting joint inflammation and bone erosion during CIA occurs via various TLR4 ligands arising at different stages of disease. The data also suggests that Blockade of TLR4 with monoclonal antibodies is a promising strategy in RA treatment.Entities:
Keywords: Endogenous ligands; Monoclonal antibody; Osteoclasts; Rheumatoid arthritis; Toll-like receptor 4 (TLR4)
Mesh:
Substances:
Year: 2016 PMID: 27510283 DOI: 10.1002/eji.201646453
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532